Benitez A, Torralba K, Ngo M, et al. - Peripheral blood mononuclear cells were isolated from healthy donors and individuals with SLE on Belimumab or standard-of-care therapy (SCT) in order to assess the impacts of the B-cell activating factor (BAFF)-targeting antibody Belimumab on human nonmemory B-cell pools. In comparison with healthy donors and SCT individuals, patients who were treated with Belimumab exhibited modifications in the nonmemory B-cell pool identified by a reduction in the Transitional 2 (T2) subset, and a rise in the proportion of Transitional 1 (T1) cells. No important variations between the groups was demonstrated by the naïve B-cell compartment. Therefore, it was manifested using a translational strategy that Belimumab-mediated BAFF depletion decreases the T2 subset in individuals, comparable to what is noted in mouse models with BAFF depletion.